A Study on the Value of Combination Chemotherapy with Etoposide, Adriamycin and Cisplatin as a Postoperative Adjuvant Chemotherapy for Stage III and Mastric Cancer

Abstract

In order to investigate the value of EAP therapy as a postoperative adjuvant chemotherapy for advancedgastric cancer, 12 patients with stage Itr gastric cancer and 13 patients with stage IV gastric cancer were treated by10 mglbody of mitomycin C on the day of surgery and 3 courses of EAP therapy (etoposide 60 mg/m2 ×3, adrimycin20 mg/m² ×2, cisplatin 40 mg/m² ×2) 3 weeks, 3 months and 6 months after surgery. Since bone mairow toxicityand nephrotoxicity were controllable, the treatments were carried out safely in all cases. The survival rate of the EAP therapy group was significantly better than that of the historical control goup in stage IV (p=0.0358), whereas there was no significant difference in stage III. The results of questionnaires indicated that the patientscould tolerate the side effects of EAP therapy. In conclusion, EAP therapy is a safe and effective treatment as apostoperative adjuvant chemotherapy for advanced gastric cancer.